FDA Approves KLYGEFA™ for Generalized Myasthenia Gravis

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Therapeutic advances in LGMD 2I/R9

Activity Snapshot

Activity Type: 
Live, Virtual Webinar
Release Date: 
Thursday, December 10, 2026
Activity Overview: 

4:00 PM ET
Finally, a therapeutic option for patients living with LGMD 2I/R9. An overview of BBP-418 phase 2 and 3 efficacy and safety data.